vinyl-methyl-oxazolidone | 115148-35-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: vinyl-methyl-oxazolidone
• 英文别名: vinyl-methyloxazolidone；vinylmethyloxazolidone；Vinyl-Methyl-Oxazolidinon；4-ethenyl-3-methyl-1,3-oxazolidin-2-one
• CAS: 115148-35-1
• 化学式: C₆H₉NO₂
• 分子量: 127.143
• InChiKey: SUBDDZAVMRBUMP-UHFFFAOYSA-N

物化性质

• 沸点：
  262.5±29.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  [(E)-4-(methylcarbamoyloxy)but-2-enyl] N-methylcarbamate 在 tris(dibenzylideneacetone)dipalladium (0) 、 1,2-双(二苯基膦)乙烷 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 以24%的产率得到vinyl-methyl-oxazolidone
  参考文献：
  名称：

  Palladium(0)-catalyzed cyclization of 2-butenylene dicarbamates forming 4-vinyl-2-oxazolidones

  摘要：

  DOI：

  10.1016/s0040-4039(00)96638-3

文献信息

• Personal care compositions comprising hydrophobically modified cationic polymers
  申请人：Carnali Oreste Joseph

  公开号：US20070259795A1

  公开（公告）日：2007-11-08

  The invention provides personal care/personal wash compositions comprising hydrophobically modified cationic polymers which enhance deposition of benefit agent.

  这项发明提供了含有疏水修饰阳离子聚合物的个人护理/洗涤组合物，可增强益处剂的沉积。
• Compositions for delivery of therapeutics and other materials, and methods of making and using the same
  申请人：——

  公开号：US20030224974A1

  公开（公告）日：2003-12-04

  In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and an active agent.

  本发明的部分涉及包含载体、金属结合域、金属离子和活性剂的组合物。
• Compositions for treatment with glucagon-like peptide, and methods of making and using the same
  申请人：Bolotin M. Elijah

  公开号：US20050260259A1

  公开（公告）日：2005-11-24

  In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1.

  本发明部分涉及包含载体、金属结合域、金属离子和GLP-1的组合物。
• Antagonists of the bradykinin B1 receptor
  申请人：Ng Gordon

  公开号：US20090048149A1

  公开（公告）日：2009-02-19

  The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can be used therapeutically or prophylactically against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

  本发明涉及一种治疗、预防或缓解与或通过B1活性介导的疾病或病状的方法，该方法涉及给予一种包含与多价载体共轭的缓激肽的布雷金肽B1受体拮抗剂组成物的方法，包括与多价聚乙二醇共轭的缓激肽。该方法可用于治疗或预防与布雷金肽B1受体相关的疾病或病状，如炎症或疼痛。
• [EN] UV CURABLE INKJET INKS AND INKJET PRINTING METHODS<br/>[FR] ENCRES POUR JET D'ENCRE DURCISSABLE AUX UV ET PROCÉDÉS D'IMPRESSION À JET D'ENCRE
  申请人：AGFA NV

  公开号：WO2022106100A1

  公开（公告）日：2022-05-27

  A UV curable inkjet ink including a free radical polymerizable compound and an acyl phosphine oxide initiator wherein the acyl phosphine oxide initiator includes an acyl group selected from the group consisting of a benzoyl group substituted by an urea group or an oxalylamide group; a 2,6-dimethyl benzoyl group substituted in position 3 by an urea group or an oxalylamide group; a 2,6-dimethoxy benzoyl group substituted in position 3 by an urea group or an oxalylamide group; a 2,4,6-trimethyl benzoyl group substituted in position 3 by an urea group or an oxalylamide group; and a 2,4,6-trimethoxybenzoyl group substituted in position 3 by an urea group or an oxalylamide group wherein the urea group and the oxalylamide group include a tertiary amine group positioning a phosporus atom of the acylphosphine oxide initiator in a 1 to Z position, where position 1 is defined as that of the phosphorus atom and position Z is defined as the nitrogen atom of the tertiary amine group with Z representing an integer of at least 11; and that the acyl phosphine oxide initiator contains no more than two photoinitiating moieties having a phosphine oxide group.

  一种紫外光固化喷墨墨水，包括自由基聚合化合物和酰基膦氧化物引发剂，其中酰基膦氧化物引发剂包括以下酰基：被尿素基或草酰胺基取代的苯甲酰基；在3位被尿素基或草酰胺基取代的2,6-二甲基苯甲酰基；在3位被尿素基或草酰胺基取代的2,6-二甲氧基苯甲酰基；在3位被尿素基或草酰胺基取代的2,4,6-三甲基苯甲酰基；在3位被尿素基或草酰胺基取代的2,4,6-三甲氧基苯甲酰基，其中尿素基和草酰胺基包括将膦氧化物引发剂的磷原子定位于1到Z位置的三级胺基，其中位置1被定义为磷原子的位置，位置Z被定义为三级胺基的氮原子，其中Z表示至少为11的整数；而且酰基膦氧化物引发剂不含有超过两个具有膦氧化物基团的光引发基团。